Coral Laboratories Limited

As of June 30, 2026, Coral Laboratories Limited carries a market capitalization of 2.25B, placing it among publicly traded companies globally. Its enterprise value stands at 2.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Coral Laboratories Limited has 3.57M shares outstanding.

As of June 30, 2026, Coral Laboratories Limited trades at a trailing price-to-earnings ratio of 11.72.

As of June 30, 2026, Coral Laboratories Limited trades at an EV/EBITDA multiple of 11.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 13.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.25B versus a market cap of 2.25B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.59M in revenue per employee across its workforce of 173.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Coral Laboratories Limited recorded 71.34M in income tax expense. That works out to an effective tax rate of 27.08, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 263.41M, leaving 192.08M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Coral Laboratories Limited's stock has gained approximately 1.86% over the past 52 weeks. The 50-day moving average sits at 582.30, while the 200-day moving average is 505.41.

Over the twelve months ended June 30, 2026, Coral Laboratories Limited generated 967.01M in revenue and converted that into 192.08M in net income, yielding earnings per share of 53.76. EBITDA reached 188.31M, while operating income came in at 161.73M.

Over the twelve months ended June 30, 2026, Coral Laboratories Limited posted a gross margin of 58.16, reflecting its pricing power and cost economics. The operating margin of 16.73 and net profit margin of 19.86 provide insight into operational efficiency.